[Pharmacodynamic profile and clinical efficacy of moxifloxacin ophthalmic solution (Vegamox 0.5% ophthalmic solution].
Watanabe
Masakazu
M
Masakazu.Watanabe@AlconLabs.com
Ishizuka
Keiji
K
Ikemoto
Toshio
T
D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D001372:Aza Compounds / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D001419:Bacteria / Q000187:drug effects; D002648:Child; D024841:Fluoroquinolones; D006801:Humans; D000077266:Moxifloxacin; D011804:Quinolines / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin